Although epidermal growth factor receptor (EGFR) inhibitors have been used to treat non-
small cell lung cancer (NSCLC) for decades with great success in patients with EGFR …

Non-small cell lung cancer (NSCLC) is still the leading cause of cancer-related death, and
the treatment of advanced NSCLC relies on systemic treatments. During the last decade …

Preclinical modeling suggests that intermittent BRAF inhibitor therapy may delay acquired
resistance when blocking oncogenic BRAF V600 in melanoma,. We conducted S1320, a …

Somatostatin receptor 2 (SSTR2) is overexpressed in a majority of neuroendocrine
neoplasms, including small‐cell lung carcinomas (SCLCs). SSTR2 was previously …

Background Whether a combination of chemotherapy and erlotinib is beneficial for
advanced non-small cell lung cancer (NSCLC) remains controversial. This study aimed to …

First-generation reversible EGF receptor (EGFR) tyrosine kinase inhibitors (TKIs) changed
our understanding of advanced non-small-cell lung cancer biology and behavior. The …

Among attempts to delay development of resistance to tyrosine kinase inhibitors (TKIs) in
patients with advanced non-small cell lung cancer (NSCLC) with activating mutations of …

Background Multikinase inhibitors (MKI) are targeted molecular agents that have
revolutionized cancer management. However, there is a paucity of data concerning MKI …

Background. Pharmaco-dynamic separation of cytotoxic and targeted drugs might avoid
their mutual antagonistic effect in the treatment of advanced non-small cell lung cancer …

Introduction: Preclinical data showed that intercalated administration of epidermal growth
factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) and chemotherapy might be effective …